© Plenum Publishing Corporation 2001
Pregnancy and Birth After GnRH Agonist Treatment for Induction of Final Oocyte Maturation in a Woman Undergoing Ovarian Stimulation for ICSI, Using a GnRH Antagonist (Orgalutran/Antagon) to Prevent a Premature LH Surge: A Case Report
1Division of Reproductive Medicine, Department of Obstetrics and Gynaecology, Erasmus University Medical Center, Dr. Molewaterplein 40, 3015 GD Rotterdam, The Netherlands
2Research and Development, NV Organon, Oss, The Netherlands
The Full Text of this article is available as a PDF
These references are in PubMed. This may not be the complete list of references from this article.
1. Hoff JD, Quigley ME, Yen SS. Hormonal dynamics at midcycle: A reevaluation. J Clin Endocrinol Metab. 1983;57:792–796. [PubMed] 2. Moyle WR, Bahl OP, Marz L. Role of carbohydrate of human chorionic gonadotropin in the mechanism of hormone action. J Biol Chem. 1975;250:9163–9169. [PubMed] 3. Ditkoff EC, Cassidenti DL, Paulson RJ, Sauer MV, Paul WL, Rivier J, et al. The gonadotropin-releasing hormone antagonist (Nal-Glu) acutely blocks the luteinizing hormone surge but allows for resumption of folliculogenesis in normal women. Am J Obstet Gynecol. 1991;165:1811–1817. [PubMed] 4. Olivennes F, Alvarez S, Bouchard P, Fanchin R, Salat-Baroux J, Frydman R. The use of a GnRH antagonist (Cetrorelix) in a single dose protocol in IVF-embryo transfer: A dose finding study of 3 versus 2 mg. Hum Reprod. 1998;13:2411–2414. [PubMed] 5. The Ganirelix Dose-Finding Study Group A double-blind, randomized, dose-finding study to assess the efficacy of gonadotropin-releasing hormone antagonist ganirelix (Org 37462) to prevent premature luteinizing hormone surges in women undergoing ovarian stimulation with recombinant follicle stimulating hormone (Puregon®) Hum Reprod. 1998;13:3023–3031. [PubMed] 6. Albano C, Smitz J, Camus M, Riethmuller-Winzen H, Van Steirteghem A, Devroey P. Comparison of different doses of gonadotropin-releasing hormone antagonist Cetrorelix during controlled ovarian hyperstimulation. Fertil Steril. 1997;67:917–922. [PubMed] 7. de Jong D, Macklon NS, Fauser BCJM. Apilot study involving minimal ovarian stimulation for in vitro fertilization: Extending the ''follicle stimulating hormone (FSH) window'' combined with the gonadotropin-releasing hormone antagonist cetrorelix. Fertil Steril. 2000;73:1051–1054. [PubMed] 8. Gordon K, Williams RF, Danforth DR, Hodgen GD. A novel regimen of gonadotropin-releasing hormone (GnRH) antagonist plus pulsatile GnRH: controlled restoration of gonadotropin secretion and ovulation induction. Fertil Steril. 1990;54:1140–1145. [PubMed] 9. Gonen Y, Balakier H, Powell W, Casper RF. Use of gonadotropin-releasing hormone agonist to trigger follicular maturation for in vitro fertilization. J Clin Endocrinol Metab. 1990;71:918–922. [PubMed] 10. Olivennes F, Fanchin R, Bouchard P, Taieb J, Frydman R. Triggering of ovulation by a gonadotropin-releasing hormone (GnRH) agonist in patients pretreated with a GnRH antagonist. Fertil Steril. 1996;66:151–153. [PubMed] 11. Nelson LR, Fujimoto VY, Jaffe RB, Monroe SE. Suppression of follicular phase pituitary-gonadal function by a potent new gonadotropin-releasing hormone antagonist with reduced histamine-releasing properties (ganirelix) Fertil Steril. 1995;63:963–969. [PubMed] 12. Huisman GJ, Fauser BC, Eijkemans MJ, Pieters MH. Implantation rates after in vitro fertilization and transfer of a maximum of two embryos that have undergone three to five days of culture. Fertil Steril. 2000;73:117–122. [PubMed] 13. Itskovitz J, Boldes R, Levron J, Erlik Y, Kahana L, Brandes JM. Induction of preovulatory luteinizing hormone surge and prevention of ovarian hyperstimulation syndrome by gonadotropin-releasing hormone agonist. Fertil Steril. 1991;56:213–220. [PubMed] 14. Edwards RG, Lobo R, Bouchard P. Time to revolutionize ovarian stimulation. Hum Reprod. 1996;11:917–919. [PubMed] 15. Fauser BC, Devroey P, Yen SS, Gosden R, Crowley WFJ, Baird DT, et al. Minimal ovarian stimulation for IVF: Appraisal of potential benefits and drawbacks. Hum Reprod. 1999;14:2681–2686. [PubMed] 16. de Jong D, Macklon NS, Mannaerts BM, Coelingh BH, Fauser BC. High dose gonadotropin-releasing hormone antagonist (ganirelix) may prevent ovarian hyperstimulation syndrome caused by ovarian stimulation for in-vitro fertilization. Hum Reprod. 1998;13:573–575. [PubMed] 17. Romeu A, Monzo A, Peiro T, Diez E, Peinado JA, Quintero LA. Endogenous LH surge versus hCG as ovulation trigger after low-dose highly purified FSH in IUI: A comparison of 761 cycles. J Assist Reprod Genet. 1997;14:518–524. [PMC free article] [PubMed]
Keywords: GnRH agonist, GnRH antagonist, oocyte maturation, ovarian stimulation, intracytoplasmic sperm induction, premature LH surge, ovarian hyperstimulation syndrome, amenorrhea